A predictive nomogram for short‐term outcomes of myasthenia gravis patients treated with low‐dose rituximab
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14761 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Yufan Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Rituximab, Myasthenia Gravis, Nomograms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Science and Technology Major Project, ZJLab, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
This study aims to establish and validate a predictive nomogram for the short‐term clinical outcomes of myasthenia gravis (MG) patients treated with low‐dose rituximab.
Methods
We retrospectively reviewed 108 patients who received rituximab of 600 mg every 6 months in Huashan Hospital and Tangdu Hospital. Of them, 76 patients from Huashan Hospital were included in the derivation cohort to develop the predictive nomogram, which was externally validated using 32 patients from Tangdu Hospital. The clinical response is defined as a ≥ 3 points decrease in QMG score within 6 months. Both clinical and genetic characteristics were included to screen predictors via multivariate logistic regression. Discrimination and calibration were measured by the area under the receiver operating characteristic curve (AUC‐ROC) and Hosmer–Lemeshow test, respectively.
Results
Disease duration (OR = 0.987, p = 0.032), positive anti‐muscle‐specific tyrosine kinase antibodies (OR = 19.8, p = 0.007), and genotypes in FCGR2A rs1801274 (AG: OR = 0.131, p = 0.024;GG:OR = 0.037, p = 0.010) were independently associated with clinical response of post‐rituximab patients. The nomogram identified MG patients with clinical response with an AUC‐ROC (95% CI) of 0.875 (0.798–0.952) in the derivation cohort and 0.741(0.501–0.982) in the validation cohort. Hosmer–Lemeshow test showed a good calibration (derivation: Chi‐square = 3.181, p = 0.923; validation: Chi‐square = 8.098, p = 0.424).
Conclusions
The nomogram achieved an optimal prediction of short‐term outcomes in patients treated with low‐dose rituximab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
- Huashan Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China.
- National Center for Neurological Diseases, Shanghai, China.
- Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
- Department of Neurology, Banan Hospital, Chongqing Medical University, Chongqing, China.
ORCID-Profile: Yufan Zhou, Sushan Luo, Chongbo Zhao, Ting Chang
Förderung
- Shanghai Municipal Science and Technology Major Project
- ZJLab
- National Natural Science Foundation of China
- National Key Research and Development Plan of China
Zitieren
APA
Zhou, Y., Guo, R., Xia, X., Jing, S., Lu, J., Ruan, Z., Luo, S., Huan, X., Zhao, C., Chang, T., & Xi, J. (2024). A predictive nomogram for short‐term outcomes of myasthenia gravis patients treated with low‐dose rituximab. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14761
Vancouver
Zhou Y, Guo R, Xia X, Jing S, Lu J, Ruan Z, et al. A predictive nomogram for short‐term outcomes of myasthenia gravis patients treated with low‐dose rituximab. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14761
BibTeX
@article{Zhou2024,
author = {Zhou, Yufan and Guo, Rongjing and Xia, Xingyu and Jing, Sisi and Lu, Jun and Ruan, Zhe and Luo, Sushan and Huan, Xiao and Zhao, Chongbo and Chang, Ting and Xi, Jianying},
title = {A predictive nomogram for short‐term outcomes of myasthenia gravis patients treated with low‐dose rituximab},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14761}
}
EUVIMED